Skip to content
OpenCapital
Get started

Quest Diagnostics DGX EPS (Diluted)

EPS (Diluted) at other companies

Myriad Genetics logo
Myriad GeneticsMYGN
-$0.36—
Labcorp Holdings logo
Labcorp HoldingsLH
$3.35+32.9%
Opko Health logo
Opko HealthOPK
-$0.07+30.0%
Exagen Inc. logo
Exagen Inc.XGN
-$0.17+15.0%
Personalis, Inc. logo
Personalis, Inc.PSNL
-$0.29-61.1%
Sera Prognostics logo
Sera PrognosticsSERA
-$0.17+15.0%

Other financials

Income statement

See full
Revenue$2.9B+9.2%
Gross profit$942.0M+9.2%
Operating income$399.0M+15.3%
Net income$252.0M+14.5%

Balance sheet

See full
Cash & equivalents$393.0M+109%
Total debt$6.4B-2.5%
Total equity$7.4B+6.3%
Total assets$16.7B+5.5%

Cash flow

See full
Operating cash flow$278.0M-11.5%
CapEx$114.0M-2.6%
Free cash flow$164.0M-16.8%

Valuation

See full
Market cap$23.46B+20.8%
Enterprise value$29.48B+15.7%
P/E22.9×+2.5×
P/S2.1×+0.2×

Profitability

See full
Gross margin33.2%+0.4pp
Operating margin14.3%+0.6pp
Net margin9.1%+0.2pp
FCF margin11.8%+1.4pp

Returns & leverage

See full
Return on equity14.3%+0.9pp
Debt / equity0.9×-0.1×
Current ratio1.2×-0.3×

Where this comes from

Reported directly by Quest Diagnostics in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The official record: Quest Diagnostics’s 10-Q, filed April 22, 2026, on SEC EDGAR. View the filing →

Ask your AI about Quest Diagnostics's eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Quest Diagnostics's EPS (diluted)?
Quest Diagnostics (DGX) reported EPS (diluted) of $2.24 in Q1 2026.
How has Quest Diagnostics's EPS (diluted) changed year-over-year?
Quest Diagnostics's EPS (diluted) increased by 15.5% year-over-year, from $1.94 to $2.24.
What is the long-term trend for Quest Diagnostics's EPS (diluted)?
Over 4 years (2021 to 2025), Quest Diagnostics's EPS (diluted) has grown at a -13.4% compound annual growth rate (CAGR), from $15.58 to $8.75.
What does EPS (diluted) mean?
Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.